Sanofi Stock News

Sanofi: Our Next Value Pick

The U.S. Food and Drug Administration ((FDA)) approved Sanofi''s (SNY) Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with…

Enjaymo is intended to reduce the need for red blood cell transfusion caused due to hemolysis in CAD patients. The drug is a humanised monoclonal antibody that selectively The post US FDA approves Sanofis Enjaymo for cold agglutinin disease treatment appeared first on Pharmaceutical Business review .

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big pharma earnings. The sector came back up in the final session for a firm finish. Merck & Co., Inc. (NASDAQ: MRK ) issued mixed 2022 guidance and Swiss pharma giant Roche Holding AG (OTC: RHHBY ) warned of slowing growth in 2022. Biogen, Inc. (NASDAQ: BIIB ) shares moved to the downside as they reacted to weak guidance and not-so-promising commentary about sales of the company''s Alzheimer''s drug Aduhelm. On the regulatory front, the Food and Drug Administration approved Viatris Inc.''s (NASDAQ: VTRS ) generic version of AbbVie, Inc.''s (NYSE: ABBV ) dry eye disease drug Restasis. Sanofi (NASDAQ: SNY ) received the nod for its medication Enjaymo, targeting a rare blood disorder known as cold agglutinin disease. LogicBio Therapeutics, Inc. (NASDAQ: LOGC ) shares shed over 50% during the week after the FDA imposed a clinical hold on a Phase 1/2 study of its AAV-delivered genomic editing therapy LB-001 to treat a rate metabolic disorder in children.

Sanofi (SNY) CEO Paul Hudson on Q4 2021 Results - Earnings Call Transcript

Sanofi CFO Jean-Baptiste de Chatillon joins Yahoo Finance's Anjalee Khemlani to discuss the company's earnings, the launch of another mRNA vaccination, and the outlook on COVID-19 vaccines.

Sanofi (SNY) ADRs are trading marginally lower in the pre-market on Friday after the French drugmaker failed to meet analyst estimates with its Q4 2021 revenue even as the earnings

Sanofi (SNY) beats fourth-quarter estimates for earnings but misses the same for sales. Dupixent drives sales growth, offsetting lower vaccine sales.

Sanofi press release (SNY): Q4 Non-GAAP EPS of 1.38 beats by 0.02.Revenue of 9.99B misses by 120M (+6.5% Y/Y).Specialty Care advanced to the largest business unit by sales (

Sanofi SA's SNY Q4 FY21 sales grew 4.1% to €9.99 billion, +6.5% (+4.1% on constant exchange rates). Get the Inside Access Traders Are Using to Profit More and Win Bigger.

French drugmaker Sanofi said it would aim to further increase its earnings per share (EPS) this year as it reported rising fourth-quarter results on Friday.

Sanofi <> is estimated to announce Q4 earnings results on Friday, February 4, 2022, before the market opens.The consensus EPS estimate is €1.36 and Revenue estimate is €10.11B.In…

After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned. About 3 new molecular entities, or NMEs, were approved during the month, including Immunocore Holdings plc''s (NASDAQ: IMCR ) Kimmtrak for certain patients with advanced eye melanoma and Pfizer, Inc.''s (NYSE: PFE ) atopic dermatitis treatment Cibinqo. NME approval is an important indicator to measure innovation in drug research. NME approvals totaled 50 in 2021, almost equaling the numbers of the previous year. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN )- Sanofi (NASDAQ: SNY ), however, failed to get the nod for expanding the Libtayo label to include cervical cancer. Pfizer also faced rejection for its pediatric growth hormone deficiency treatment Somatrogon. A PDUFA date is the date/period by which the Food and Drug Administration is required to announce its verdict on a sponsor company''s regulatory application. This will determine the fate of millions of dollars invested in developing the treatment from the preclinical-stage to clinical testing.

Key Events This Week: ECB, BOE, Payrolls, Euro CPI And Earnings Galore It''s a relatively busy week with several key central bank announcements, notably from the ECB and BOE, as well as European CPI updates and the US payrolls report on Friday. Starting with the ECB, Deutsche Bank economists now expect a policy rate liftoff in December 2022 of 25bps, a view apparently shared by the market this morning. Theyre also anticipating a faster pace of tightening, with 25bp hikes in the deposit rate per quarter from December 2022, until rates reach +0.5% in September 2023. In terms of what it means for this February meeting, they write in their preview that they expect the slow, step-by-step pivot to exit will continue. Their view is that President Lagarde will reiterate the ECBs capacity to act once the inflation criteria in the rates guidance are met, whilst at the same time differentiating the needs of the Euro Area from the US. The other central bank decision that day is from the Bank of England, where expectations are for the BoE to follow up their December rate hike with another 25bps increase, taking the Bank Rate to 0.5%.